Conference Coverage

Osteoporosis drugs don’t worsen COVID-19 risk, may help


 

Data supporting the guidelines

Of the 2,102 patients in the study by Blanch-Rubió and colleagues, 80.5% were women, and their mean age was 66.4 years. Overall, 63.7% had osteoarthritis, 43.5% had osteoporosis, and 27.2% had fibromyalgia. Treatments included vitamin D in 62%, calcium in 23.3%, denosumab in 12.6%, and intravenous zoledronate in 8.5%. Over half were taking analgesics and nearly a third antidepressants, with 9.9% taking duloxetine.

During the study period, 5.2%, or 109 individuals, were diagnosed with COVID-19 based on presenting for medical care with hallmark symptoms.

After adjustments for sex, age, diabetes, pulmonary disease, cardiovascular disease, chronic kidney disease, and active cancer or treatment, the relative risks for COVID-19 were 0.58 for denosumab, 0.62 for intravenous zoledronate, and 0.64 for calcium, all nonsignificant trends. No associations were found between COVID-19 and oral bisphosphonates, vitamin D, or thiazide diuretics. Increased but nonsignificant relative risks for COVID-19 were seen with analgesics, particularly pregabalin (1.55), gabapentin (1.39), and opioids (1.25).

Among antidepressants, there was a relative risk of 1.54 for selective serotonin reuptake inhibitors, 1.38 for amitriptyline, and 1.22 for all dual-action antidepressants together. In contrast, there was a negative association with the dual-action antidepressant duloxetine, with an adjusted relative risk of 0.68.

“The good news,” Dr. Drake said, “is that none of it appears bad.”

Dr. Blanch-Rubió has received grants or consulting fees from Amgen, Laboratorio Stada, Gedeon-Rhicter Ibérica, Lilly España, Pfizer, Gebro Pharma, and UCB Pharma. Dr. Maldonado has received research grants or consulting fees from Aelis, Almirall, Boehringer Ingelheim, BrainCo, Esteve, Ferrer, GlaxoSmithKline, Grünenthal, GW Pharmaceuticals, Janus, Lundbeck, Pharmaleads, Phytoplant, Rhodes, Sanofi, Spherium, Union de Pharmacologie Scientifique Appliquée, Upjohn, and Uriach. Dr. Drake has reported no relevant financial relationships.

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Search for a snakebite drug might lead to a COVID treatment, too
MDedge Endocrinology
Patients with mental illness a priority for COVID vaccine, experts say
MDedge Endocrinology
Should our patients really go home for the holidays?
MDedge Endocrinology
Nearly 10% of hospitalized patients with COVID-19 later readmitted
MDedge Endocrinology
AMA creates COVID-19 CPT codes for Pfizer, Moderna vaccines
MDedge Endocrinology
New reports guide return to play in athletes with COVID-19
MDedge Endocrinology
Nearly one in five develop mental illness following COVID-19
MDedge Endocrinology
Situation ‘dire’ as COVID spike in West, Midwest worsens, experts say
MDedge Endocrinology
Escalate HIV adherence strategies amid COVID-19
MDedge Endocrinology
In those with obesity, will losing weight cut COVID-19 severity?
MDedge Endocrinology